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 Background: In times of limited organs for transplantation, anti-HBc-positive organs can be accepted for lung transplanta-
tion to increase the number of donors. Transplant recipients should be vaccinated against hepatitis B to pre-
vent HBV infection. However, response after HBV vaccination has only been poorly evaluated in patients with 
end-stage pulmonary disease.
 Material/Methods: Anti-HBs titers of 40 anti-HBc negative patients with end-stage pulmonary disease evaluated for lung trans-
plantation were analyzed with the Architect® system (Abbott, Germany). Responders, partial responders, or 
non-responders after HBV vaccination were defined by anti-HBs titers >100 IU/L, 10–100 IU/L, and <10 IU/L, 
respectively.
 Results: There were 34/40 individuals (85%) vaccinated against hepatitis B, and 6 were not vaccinated. Response, par-
tial response, and non-response after vaccination were observed in 10/34 (29.4%), 11/34 (32.4%), and 13/34 
(38.2%) of patients, respectively. Response to vaccination did not correlate with sex, pulmonary disease, co-
morbidities, immunosuppressive therapy, or smoking status.
 Conclusions: Although 85% of patients evaluated for lung transplantation were vaccinated against hepatitis B, 38.2% did 
not show an anti-HBs titer >10 IU/L. Thus, anti-HBs titers should be regularly monitored. Nonresponders should 
be considered for booster vaccinations, alternative vaccination schedules, or prophylactic treatment with a 
nucleos(t)ide analogue in case of transplantation of an anti-HBc–positive organ.
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Background
In times of limited donor resources for any solid organ trans-
plantation, including lung transplantation for end-stage pul-
monary disease, there is a mismatch between the number of 
transplant candidates and the number of available organs. One 
option to narrow this gap is to accept organs from anti-HBc-
positive donors to increase the number of available organs. 
Anti-HBc-positive individuals account for up to 15–20% of all 
potential donors; therefore, inclusion of this population re-
sults in a substantial increase of potential donor organs [1,2]. 
Survival of recipients of anti-HBc-positive lung transplants is 
not impaired compared to recipients of anti-HBc–negative or-
gans [3]; however, there is a risk of acquiring chronic hepatitis 
B virus (HBV) infection after transplantation [4].
An effective strategy to prevent HBV transmission is vaccination 
of the anti-HBc-negative transplant recipient. Hepatitis B vac-
cination with recombinant HBsAg should be performed when 
candidates are on the waiting list prior to transplantation be-
cause its efficacy will be limited thereafter due to necessary 
immunosuppression [5,6]. The standard vaccination course in-
cludes 3 intramuscular vaccinations at the time points zero, 
month 1, and month 6 [7].
Unfortunately, systematic data from hepatitis B vaccination 
programs in patients wait-listed for lung transplantation are 
scarce. In a Spanish survey all transplant centers reported to 
perform hepatitis B vaccination, however, detailed data whether 
all three necessary vaccinations were completely administered 
or resulted in anti-HBs titers > 100 U/L were not published [2]. 
Monocentric data on 96 lung transplantation candidates de-
scribed overall anti-HBs response rates of 54% after stan-
dard or accelerated vaccination schedules [5]. Alternatively, 
response rates may increase more after high-dose compared 
to standard-dose vaccination regimens [8]. Additionally, retro-
spective data on US heart transplant recipients indicate that 
only 13/29 patients achieved a sufficient anti-HBs titer after 
a standard intramuscular vaccination schedule with 10 µg of 
recombinant HBsAg [9].
With respect to these limited data, the aim of the current 
study was to systematically characterize the hepatitis B vac-
cination program and the resulting anti-HBs titers in patients 
wait-listed for lung transplantation at our transplant center.
Material and Methods
All individuals with end-stage pulmonary disease listed for 
lung transplantation at our hospital between May 2014 and 
February 2015 were consecutively evaluated. Vaccination status 
of anti-HBc-negative patients was retrospectively determined 
by vaccination cards. In Germany, these vaccination cards are 
paper booklets distributed during childhood to document any 
vaccination administered during the lifetime.
Hepatitis B vaccinations were performed intramuscularly with 
recombinant HBsAg with the licensed vaccines Engerix® (20 µg), 
Twinri (20 µg), HBVAXpro® (10 µg), or GenH-B-Vax® (10 µg).
Anti-HBc and anti-HBs titers were analyzed with the Architect® 
system (Abbott, Wiesbaden, Germany). Responders, partial re-
sponders, or non-responders after HBV vaccination were de-
fined by anti-HBs titers >100 IU/L, 10–100 IU/L, and <10 IU/L, 
respectively [7].
Concomitant medications were extracted from medi-
cal charts. Patients with ongoing prednisolone therapy 
(2.5–20 mg per day) or repetitive prednisolone bolus thera-
py (40–100 mg) were classified as “long-term prednisolone” 
treatment. Immunosuppressants other than prednisolone 
were not used.
Data analysis was performed using Excel (Microsoft, Redmond, 
WA, USA). Statistical differences were analyzed by Fisher´s ex-
act test (GraphPad Software, La Jolla, CA, USA). A p-value <0.05 
was considered as statistically significant.
The project was evaluated and approved by the Ethics 
Committee of the University of Leipzig (ethics vote number 
170-14-02062014). All patients provided written informed 
consent prior to any study-related procedures.
Results
Baseline characteristics of the study population
During the study period, 61 patients with end-stage pulmonary 
disease were evaluated or wait-listed for lung transplantation; 
21 were excluded due to classification as non-transplant candi-
dates (n=9), positive anti-HBc titers (n=2), death (n=2), trans-
plantation (n=4), or incomplete data (n=4). Thus, the study 
population consisted of 40 anti-HBc-negative patients (50% 
female, age 57.2±9.9 years, COPD n=24/40, long-term pred-
nisolone therapy n=9/40, history of smoking n=30/40). Further 
baseline characteristics are summarized in Table 1. Only 1 of 
the patients had clinically relevant liver disease, and this pa-
tient presented with compensated Child A cirrhosis due to al-
pha-1 antitrypsin deficiency.
Patients considered for further analysis did not significant-
ly differ from excluded cases concerning, age, sex, etiology of 
end-stage pulmonary disease, long-term steroid therapy, or 
concomitant diseases.
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Hepatitis B vaccination schedules
Hepatitis B vaccination was performed in 34/40 (85%) patients 
prior to wait-listing for lung transplantation. There were 6/40 
(15%) individuals who were not vaccinated, and 10/34 (29.4%) 
and 24/34 (70.6%) of cases received 2 or 3 or more vaccina-
tions, respectively. Baseline vaccination was performed with 
Engerix®, Twinrix®, HBVAXpro®, or GenH-B-Vax® in 15, 15, 1, 
and 2 patients, respectively. One hepatitis vaccine could not 
be identified in the vaccination card. The median interval be-
tween the baseline vaccination and the 2 booster vaccinations 
was 5 (minimum 1, maximum 1125) weeks and 30 (minimum 
3, maximum 363) weeks (Table 2). Four patients received more 
than 3 vaccinations (maximum 7 vaccinations during a time 
span of 15 years).
One patient received the baseline and first booster vaccina-
tion within 1 week as part of an accelerated vaccine sched-
ule due to expected timely transplantation. Vaccinations with 
higher than the standard vaccine dose were not performed. 
Anti-HBs response was analyzed 36.5 (minimum 1, maximum 
805) weeks after the last hepatitis B vaccination.
Baseline 
characteristics
Total 
population
n=40
Non- 
(Hepatitis B-) 
vaccinated 
population
n=6
(Hepatitis B-) 
vaccinated 
population
n=34 
Responders
n=10 
(29.4%)
Partial 
responders
n=11 
(32.4%)
Non-
responders
n=13 
(38.2%)
P-Values 
(correlation 
with 
response)
 Women (%)  20 (50.0)  3 (50.0)  17 (50.0)  8 (80.0)  2 (18.2)  7 (53.8)
 Men (%)  20 (50.0)  3 (50.0)  17 (50.0)  2 (20.0)  9 (81.8)  6 (46.2)
 Median age, years  59.4 (26–27) 58.0 (26–66) 59.4 (28–67) 60.3 (52–64) 59.9 (28–67) 59.4 (54–66)
 Median BMI kg/m2  23.0 (15–37) 23.0 (19–27) 23.0 (15–37) 22.5 (15–27) 23.0 (19–37) 24.0 (21–33)
Number of hepatitis B vaccinations
 Three or more (%)  24 (60.0)  0 (0.0)  24 (70.6)  8 (80.0)  8 (72.7)  8 (61.5)
 Two (%)  10 (25.0)  0 (0.0)  10 (29.4)  2 (20.0)  3 (27.3)  5 (38.5)
 None (%)  6 (15.0)  6 (100) 0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
Lung disease
 COPD (%)  24 (60.0)  3 (50.0)  21 (61.8)  8 (80.0)  4 (36.4)  9 (69.2)
0.2508
 Non-COPD (%)  16 (40.0)  3 (50.0)  13 (38.2)  2 (20.0)  7 (63.3)  4 (30.8)
Co-morbidities
 Diabetes mellitus (%)  8 (20.0)  3 (50.0)  5 (14.7)  0 (0.0)  3 (27.3)  2 (15.4) 0.2908
  Renal Insufficiency (%) 
GFR <90 mi/min/1.73 m2
 20 (50.0)  4 (66.6)  16 (47.0)  7 (70.0)  4 (36.4)  5 (38.5) 0.1341
  Renal Insufficiency (%) 
GFR <60) 
mi/min/1.73 m2
 2 (5.0)  0 (0.0)  2 (5.8)  0 (0.0)  1 (9.1)  1 (7.7) 1.0000
Smoking status
 Ex-smoker (%)  30 (75.0)  3 (50.0)  27 (79.4)  7 (70.0)  9 (81.8)  11 (84.6)
0.3943
 Never-smoker (%)  10 (25.0)  3 (50.0)  7 (20.6)  3 (30.0)  2 (18.2)  2 (15.4)
Long-term prednisolone therapy
 Yes (%)  9 (25.0)  3 (50.0)  6 (20.6)  2 (20.0)  1 (9.1)  3 (30.8)
1.0000
 No (%)  31 (75.0)  3 (50.0)  28 (79.4)  8 (80.0)  10 (90.9)  10 (69.2)
Table 1. Baseline characteristics of the study cohort.
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Efficacy of hepatitis B vaccination
Anti-HBs titers of >100 IU/L, 10–100 IU/L, and <10 IU/L were 
observed in 10/34 (29.4%), 11/34 (32.4%), and 13/34 (38.2%) 
patients (Figure 1). Response to vaccination did not correlate 
with sex, pulmonary disease (COPD vs. non-COPD), long-term 
prednisolone therapy, smoking status, or co-morbidities. The 
age of responders, partial responders, or non-responders at 
the baseline vaccination did not differ significantly. The me-
dian time interval between the last hepatitis B vaccination 
and the titer control was 20 weeks in non-responders and 91 
weeks in responders.
Discussion
Hepatitis B vaccination is recommended in solid organ trans-
plant candidates prior to surgery [10,11], but existing data on 
hepatitis B vaccination programs in patients wait-listed for lung 
or heart transplantation are limited by small patient numbers, 
retrospective analysis, or single-center study design [5,8,9].
In our cohort, hepatitis B vaccination was administered to 85% 
of patients. Spanish data report that all national transplant 
centers regularly vaccinate against hepatitis B in patients on 
the waiting list for lung transplantation, although none quan-
tify the level of anti-HBs titers [12]. However, quantification 
of anti-HBs titers is important, because 38.2% of our vacci-
nated study population did not reach anti-HBs titers >10 IU/L 
while on the waiting list. Galar et al. reported overall anti-HBs 
response rates of 54.2% [5]. Unfortunately, they did not pro-
vide detailed anti-HBs titers, so their results are difficult to 
compare with our study.
Anti-HBs titers should be quantified 4–8 weeks after the third 
hepatitis B vaccination of a standard vaccination course [7]. 
Unfortunately, due to our retrospective study design we did 
not have any data at this time point, but analyzed the time in-
terval between the initial and the last administered hepatitis B 
vaccination and the time point of the current study evaluation.
Reasons for impaired anti-HBs immunity after vaccination are 
numerous and include advanced age at initiation of the vacci-
nation schedule, history of smoking, immunosuppression, male 
sex, and advanced end-stage pulmonary or heart disease [5,9]. 
Similar correlations were not observed in our study. These re-
sults should not be overinterpreted due to the limited num-
ber of patients and the single-center study design. In case of 
an anti-HBs titer <10 IU/L, a standardized treatment approach 
prior to transplantation has not been developed yet. It may be 
better to vaccinate with a combined hepatitis A and B vaccine 
(Twinrix®) compared to the corresponding monovalent vaccines 
(Havrix® and Engerix-B®) because this strategy might induce 
better anti-HBs responses [13]. In our cohort, an anti-HBs ti-
ter >100 IU/L was achieved by 5/10 vs. 2/10 individuals after 
3 vaccinations with Twinrix® and Engerix®, respectively. This 
Responder Partial-responder Non-responder
Total hepatitis 
B-vaccinated 
population
Median age at baseline hepatitis B 
vaccination (range)
54.1 (31/61) 51.0 (11/65) 58.5 (46/64) 56.0 (11/65)
Median time interval (in weeks) 
between baseline vaccination 
and anti-HBs titer determination 
(range)
131 (21/1014) 167 (10/1200) 47 (2/404) 51.5 (2/1200)
Median time interval (in weeks) 
between latest vaccination and 
anti-HBs titer determination 
(range)
91 (3/770) 33.5 (6/805) 20 (1/382) 36.5 (1/805)
Table 2. Details of hepatitis B vaccination schedules.
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Figure 1.  Individual anti-HBs titers in hepatitis B vaccination 
responders, partial responders, and non-responders.
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difference was not statistically significant, but is again im-
paired by the small cohort size. Alternative treatment options 
include additional booster vaccinations [9], accelerated vac-
cination schedules [5], or high-dose booster vaccinations [8]. 
However, these alternatives have not been evaluated in large 
prospective controlled trials and reach sufficient anti-HBs ti-
ters in only about 50% of cases. In our cohort, 4 patients re-
ceived more than 3 hepatitis B vaccinations, and all developed 
an anti-HBs titer >10 IU/L. If booster vaccinations do not in-
duce sufficient humoral immunity, prophylactic treatment with 
an HBV nucleos(t)ide analogue (e.g., lamivudine) may be an-
other option to prevent hepatitis B infection after transplan-
tation of an anti-HBc-positive organ [14].
Conclusions
Although 85% of patients on the waiting list for lung trans-
plantation were vaccinated against hepatitis B, 38.2% did not 
present with an anti-HBs Titer >10 IU/L. Thus, titer controls 
after hepatitis B vaccination should be regularly monitored. 
In case of insufficient immunity, patients should be consid-
ered for additional booster vaccinations, alternative vaccina-
tion schedules, or prophylactic treatment with a nucleos(t)ide 
analogue to prevent hepatitis B infection in case of transplan-
tation of an anti-HBc-positive donor organ.
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